BridgeMD
Pneumococcal booster vaccine responsiveness in persons of 78-84 years of age (VIVO-2)
EU CTIS ID: 2025-521616-19-00
What this study is testing
Determine the increase in Pneumococcal antibody responses one month after PCV20 vaccination.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Born between 1941-1947
- Participating in the VIVO study in 2020
- Having had PPSV23 vaccine in 2020
- Willing to receive the PCV20 vaccine as part of the National Immunization Program in 2025
- Having signed the Informed Consent
- Understanding the goal of the study, according to the study team
You likely can't join if
- Receipt of any high-dose (≥ 20 mg of prednisone daily or equivalent) corticosteroids (locally applied including inhaled steroids are acceptable) within 2 weeks of study entry
- Repeated use of any high dose of corticosteroids (a dose of > 30 mg of prednisone or equivalent per day for multiple days) in the last month
- Receipt of an organ- or bone marrow transplant during the last 5 years
- Having an anatomical or functional asplenia
- Receipt of blood products or immunoglobulin, within one month of study entry
- Known or suspected serious coagulation disorder that in the judgement of the investigator would contraindicate against frequent blood sampling
See the full eligibility criteria
- Born between 1941-1947
- Participating in the VIVO study in 2020
- Having had PPSV23 vaccine in 2020
- Willing to receive the PCV20 vaccine as part of the National Immunization Program in 2025
- Having signed the Informed Consent
- Understanding the goal of the study, according to the study team
- Receipt of any high-dose (≥ 20 mg of prednisone daily or equivalent) corticosteroids (locally applied including inhaled steroids are acceptable) within 2 weeks of study entry
- Repeated use of any high dose of corticosteroids (a dose of > 30 mg of prednisone or equivalent per day for multiple days) in the last month
- Receipt of an organ- or bone marrow transplant during the last 5 years
- Having an anatomical or functional asplenia
- Receipt of blood products or immunoglobulin, within one month of study entry
- Known or suspected serious coagulation disorder that in the judgement of the investigator would contraindicate against frequent blood sampling
- Known to be positive for human immunodeficiency virus (HIV), and/or hepatitis C virus (HCV) and/or hepatitis B virus (HBV) (presence of HBsAg or anti HBc antibodies)
- Start of a treatment with chemotherapy within the last three months of study entry
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.